Literature DB >> 29196244

A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods.

B Burja1, T Kuret1, S Sodin-Semrl2, K Lakota3, Ž Rotar1, R Ješe1, K Mrak-Poljšak1, P Žigon1, G G Thallinger4, J Feichtinger4, S Čučnik5, M Tomšič6, S Praprotnik6, A Hočevar1.   

Abstract

Giant cell arteritis (GCA) is a primary systemic vasculitis present in subjects older than 50years with involvement of large- and medium-sized arteries. Early diagnosis for GCA is essential to prevent serious complications, such as permanent vision loss and/or cerebrovascular events. Elevated inflammatory cytokines, with acute phase and other proteins dominate large- and medium-sized arteries leading to stenosis or occlusion of arterial lumen. To date, there are no reliable serological markers for monitoring GCA. The review aims to provide concise overview of published GCA studies in order to: a) identify significantly changed serological biomarkers in GCA and compare the influences of techniques for marker evaluation and b) investigate most promising markers in GCA using analyte frequency and meta-analysis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; ELISA; Giant cell arteritis; Luminex multiarray; Serology

Mesh:

Substances:

Year:  2017        PMID: 29196244     DOI: 10.1016/j.autrev.2017.11.022

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

1.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Authors:  Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

2.  Clinical and technical determinants of positive temporal artery biopsy: a retrospective cohort study.

Authors:  Fatima Alnaimat; Ahmad T Mansour; Hamza Alduraidi; Soud Al-Qasem; Mohammad Hindi; Tala Rawashdeh; Eman Hassan; Sahar Almustafa; Refat Hanbali; Osama Ababneh
Journal:  Rheumatol Int       Date:  2021-10-18       Impact factor: 2.631

3.  Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study.

Authors:  Philipp Jud; Nicolas Verheyen; Martin H Stradner; Christian Dejaco; Dieter Szolar; René Thonhofer; Leyla Schweiger; Marianne Brodmann; Franz Hafner
Journal:  Rheumatol Int       Date:  2022-08-23       Impact factor: 3.580

4.  Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis.

Authors:  Shoichi Fukui; Ayako Kuwahara-Takaki; Nobuyuki Ono; Shuntaro Sato; Tomohiro Koga; Shin-Ya Kawashiri; Nozomi Iwanaga; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Kiyoshi Migita; Yojiro Arinobu; Hiroaki Niiro; Yoshifumi Tada; Koichi Akashi; Takahiro Maeda; Atsushi Kawakami
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

5.  Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica.

Authors:  Yannick van Sleen; Philip Therkildsen; Berit Dalsgaard Nielsen; Kornelis S M van der Geest; Ib Hansen; Peter Heeringa; Marcel D Posthumus; Maria Sandovici; Erik J M Toonen; Jannik Zijlstra; Annemieke M H Boots; Ellen-Margrethe Hauge; Elisabeth Brouwer
Journal:  Arthritis Res Ther       Date:  2022-03-07       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.